Breaking News and Updates
- Abolition Of Work
- Alternative Medicine
- Artificial Intelligence
- Atlas Shrugged
- Ayn Rand
- Basic Income Guarantee
- Chess Engines
- Cloud Computing
- Conscious Evolution
- Cosmic Heaven
- Designer Babies
- Donald Trump
- Ethical Egoism
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom of Speech
- Gene Medicine
- Genetic Engineering
- Germ Warfare
- Golden Rule
- Government Oppression
- High Seas
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Longevity
- Immortality Medicine
- Intentional Communities
- Life Extension
- Mars Colonization
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- New Utopia
- Personal Empowerment
- Political Correctness
- Politically Incorrect
- Post Human
- Post Humanism
- Private Islands
- Quantum Computing
- Quantum Physics
- Resource Based Economy
- Ron Paul
- Second Amendment
- Second Amendment
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Teilhard De Charden
- The Singularity
- Tor Browser
- Transhuman News
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Zeitgeist Movement
The Evolutionary Perspective
Category Archives: Psoriasis
Cyndi Lauper Speaks Out About Her Ongoing Battle With This Skin Condition – NewBeauty Magazine (blog)
Posted: August 25, 2017 at 3:38 am
WhenKim Kardashian Westtold the world about her ongoing problems withpsoriasis, an immune-mediated disease that causes raised, red, scaly patches to appear on the skin, it helped raise awareness for the condition. Now, another A-lister is speaking out with the same intention.
Pop icon Cyndi Lauper spoke out onGood Morning Americatoday about her battle with psoriasis and her partnership with Novartis (parent company ofCosentyx, an anti-psoriasis drug), which she hopes will help her reach those who are also suffering from the disease.
You May Also Like:Woman Posts Powerful Photos to Show What Psoriasis Feels Like
“I’m one of the 7.5 million people with it, and I just cant stress enough to not sit in the dark and not sit alone. When you’re sick, you feel isolated and powerless, but information is power, so go toSeeMeToKnow.comand you’ll hear my story and other people’s stories. What everyone continually says is don’t give upseek the treatment that’s right for you. It’s not just arash, it’s an inflammatory thing.”
Psoriasis, which according to the American Academy of Dermatology typically affects the outside of the elbows, knees or scalp, can begin at any age. “I was covered from head to toe with it (it started on myhead) and I felt badly,” says Lauper. “But I didn’t give up. I had every kind ofcrazy treatment. But what works for one person isn’t going to work for another.”
Keep a record of your symptoms and visit a board-certified dermatologist who can properly diagnose and treat you to minimize any pain or discomfort you may be experiencing.
Posted: at 3:37 am
Encore Dermatology, formed two years ago as a vehicle for three ex-Valeant products, has picked upa late-stage pipeline drug via a deal with India’s Dr. Reddy’s Laboratories.
The Malvern, Pennsylvania, company says it has licensed a steroid candidate developed by Dr. Reddy’s Promius Pharma subsidiary that has passed phase 3 testing in adults with moderate to severe plaque psoriasis and could claim U.S. approval within weeks.
Encore is paying up to $32.5 million for development, manufacturing and commercialization rights to the drug, a topical corticosteroid called DFD-06 that is administered twice daily as a cream and is also in phase 2 testing for psoriasis in children and adolescents.
If approved, the drug will slot into its portfolio alongside dermatologic creams Hylatopic and Tetrixacquired from Valeant along with acne drug BenzEFoam in 2015as well as low-potency corticosteroid cream Tridesilon (desonide) which was licensed from Perrigo and launched earlier this year for skin conditions such as atopic dermatitis.
Dr. Reddy’s has been funneling 40% of its R&D spend into biosimilars and proprietary medicinesprimarily for the U.S. marketas it tries to move beyond its heartlands in generic small-molecule drugs that have been hampered of late by regulatory compliance problems at manufacturing facilities.
So far, that drive has focused on improved formulations of established drug molecules and has resulted in two drug launches in the U.S.Zembrace Symtouch, an injectable form of sumatriptan for migraine and Sernivo, a spray formulation of the steroid drug betamethasone. The company has targeted sales of $500 million for its proprietary business within the next five years.
We believe Encore and its management team are well positioned to realize the full potential of this asset DFD-06,” said Anil Namboodiripad, Ph.D., president of Promius Pharma.
“We look forward to obtaining NDA approval this fall, enabling Encore’s management team to quickly deliver this product to the providers and their patients,” he added.
Posted: at 3:37 am
Noninvasive tests may be used as an alternative to liver biopsy and imaging for monitoring hepatic fibrosis in psoriasis patients who are taking methotrexate sodium, researchers reported.
In a small single-institution cohort study, 54 out of 69 patients (78.3%) who underwent NASH FibroSure testing prior to starting methotrexate sodium therapy had elevated steatosis scores and 27.5% had elevated fibrosis scores, according to Clayton Green, MD, PhD, of Marshfield Clinic in Marshfield, Wisc., and colleagues.
“Our results do not suggest that a liver biopsy can be entirely replaced by the NASH FibroSure test,” they wrote in JAMA Dermatology. “They do, however, support the idea that the number of liver biopsies can be significantly reduced by the use of noninvasive tests such as the NASH FibroSure.”
While there are several noninvasive proprietary tests available for monitoring the risk of progression of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), the FibroSure test is the most widely adopted test for evaluating the hepatotoxic effects of methotrexate sodium therapy.
The model is a semi-quantitative test that calculates the degree of hepatic fibrosis using computational algorithms to analyze serum levels of aminotransferases, 2- macroglobulins, haptoglobin, apolipoprotein A1, cholesterol, transpeptidase, glucose, and triglycerides, as well as age, sex, height, and weight. Its inclusion of height and weight are a unique opportunity to account for the role of BMI in the progression of steatosis to fibrosis, the researchers noted.
Green’s group conducted a descriptive retrospective analysis of 107 patients with psoriasis treated with methotrexate sodium therapy. All patients underwent NASH FibroSure testing from 2007 to 2013 at a single dermatology referral center. Of this cohort, 107 (57 women) were eligible for correlation analysis.
Among the patients who underwent NASH FibroSure testing during methotrexate therapy, the cumulative methotrexate sodium therapy dose corresponded to a statistically significant association of a higher NASH FibroSure hepatic fibrosis score in women (Spearman =0.21, P=0.02) but not in men. The correlation for women remained significant even after correcting for patients who had multiple NASH FibroSure tests, the researchers reported.
Green’s group also found a statistically significant correlation between a BMI of 28 or more and worsening fibrosis scores in women (Spearman =0.2, P=0.03), suggesting that obesity influenced the progression of fibrosis scores in women.
No significant correlations were seen between ages 65 and up and worsening of hepatic fibrosis scores with cumulative methotrexate sodium therapy dose. Additionally, there were no differences between men and women in terms of prevalence of a BMI of 28 or more, diabetes, age older than 65, or chronic kidney disease.
“Although our study design does not allow us to examine the contribution of methotrexate sodium therapy to worsening fibrosis scores, our results provide support for the application of serologic tests for the progression of NAFLD to patients with psoriasis,” the authors stated.
They explained that further analysis of differences between men and women in the progression of hepatic fibrosis by methotrexate sodium therapy dose could lead to improved treatment and monitoring recommendations.
They also noted the need for a prospective, randomized, multi-institutional analysis of NASH FibroSure and liver biopsies for patients with psoriasis receiving methotrexate sodium versus other treatments. This should specifically be a larger cohort of men and women with different racial and ethnic backgrounds, they added.
A leading study limitation was the use of a mathematical model that generated a risk score for hepatic fibrosis without offering an actual measure of fibrosis. Additionally, the cohort was uncontrolled and the change in fibrosis scores or the progression of NAFLD in patients with psoriasis remains unknown.
The study was funded by the Marshfield Clinic Resident Research Program.
Green disclosed funding from T2 Biosystems.
See the original post:
NASH FibroSure Test Useful for Tracking Fibrosis in Psoriasis – MedPage Today
Posted: at 3:37 am
Dr Reddy’s has completed Phase 3 studies, manufactured registration batches, and made preparations for a New Drug Application (NDA) filing for DFD-06, but has chosen to license the drug out rather than pursue commercialization in house.
“We look forward to obtaining NDA approval this fall, enabling Encores management team to quickly deliver this product to the providers and their patients.” says Anil Namboodiripad, SVP, Proprietary Products, and president, Promius Pharma.
Dr. Reddy’s has had a challenging year. Shares in the drugmaker began a month-long slide following the announcement of its first quarter 2018 results in July 2017, which recorded a 6% decline in revenues and a 53% fall in profits year-on-year. The lackluster results were due, in part, to price erosion from U.S. customer consolidation and a lower contribution from U.S. product launches.
The Indian drugmaker has also had a tough time with manufacturing, running afoul of stepped-up oversight from the Food and Drug Administration. In April, the regulator completed an audit of the company’s Srikakulam-based production site, flagging points where the site fell shortof regulatory standards. This inspection resulted in a Form 483, adding to similar letters issued to the company’s Miryalguda and Bachupally sites this year.
Posted: at 11:29 pm
For years, psoriasis suffers have battled patches of rough, reddened, and intensely itchy skin that can cause pain as well embarrassment, with little hope of relief.
But major breakthroughs have been logged in the treatment of this potentially debilitating disorder that affects almost 10 million Americans, including small children. And if you are suffering from the disease, its time to take action.
To spotlight the treatments that have emerged in recent years, the National Psoriasis Foundation is observing National Psoriasis Action month in August.
The NPF Foundation wants to spread the word that there have been tremendous advancements in the number of treatment options for people living with the condition. The NPF has even launched a website to educate patients, caregivers and health care professionals about the resources to treat psoriatic disease.
Throughout August, people impacted by psoriasis can participate in interactive quizzes that will help them better understand and manage their disease, Dr. Michael Siegel, Ph.D, vice president of Research Programs at the NPF tells Newsmax Health.
Psoriasis often develops between the ages of 15 and 35, but it can develop at any age. While scientists do not know exactly what causes psoriasis, it is known that the immune system and genetics play major roles in its development.
Usually, something triggers the condition to flare. The skin cells in people with psoriasis grow at an abnormally fast rate, which leads to painful lesions on the body.
The genetic link is clear, says Siegal.
If one parent has psoriasis, there is about a 10 percent chance of a child contracting it. If both parents have psoriasis, the chance increases to 50 percent, he notes.
Dr. Kenneth Beer, associate clinical professor of dermatology at the University of Miami, tells Newsmax Health that the No. 1 myth about psoriasis is that it is just dry skin.
Its far more than that, he says. Psoriasis is an immune disease in which the body stimulates growth of skin cells in an abnormal way. It is largely genetic and may be associated with stress, infection medication or a range of other issues. In addition to affecting the skin, it can frequently affect the joints of the body.
Another myth is that the condition is contagious. Not so, says Beer. And while it is not curable at this point in time, it is manageable and treatable. But if you dont take care of your psoriasis, it can lead to serious medical conditions.
According to the Mayo Clinic, people with psoriasis are at a great risk for Type 2 diabetes as well as vision problems and heart disease. About 30 percent of people who have psoriasis will develop psoriatic arthritis, according to the NPF.
Reality TV star Kim Kardashian revealed that she suffers from the condition and that stress plays a key role in her flare-ups of psoriasis. Two-time Grammy winning songstress LeAnn Rimes kept her struggle hidden until 2008 when she decided to open up about her experience as part of the Stop Hiding, Start Living awareness campaign sponsored by Abbott, which makes the psoriasis drug, Humira.
Other celebs with psoriasis include comedian Jon Lovitz and Leave it to Beaver star Jerry Mathers, who admits that the condition is no laughing matter.
Siegel says that treating psoriasis involves good disease management and paying attention overall health.
With advances in the number of treatment options available today for people living with psoriasis its easier than ever to treat the condition, he says. The biggest breakthrough came 10 years ago with the introduction of injectable biologics which changed the lives of patients and their providers.
By targeting specific pathways in the immune system, these biologics have demonstrated remarkable outcomes in clinical trials. Moving forward, scientists are likely to reveal even more effective treatments and will be able to harness the same targeted therapy for oral and topical treatments as well.
Some examples of biologic drugs to treat psoriasis include Humira, Enbrel, and Remicade.
Siegel says that some people believe that eliminating certain foods from their diet, such as gluten, dairy, sugar, or red meat can reduce inflammation and therefore lower their chances of a psoriatic flare.
Others believe that consuming certain vitamins, herbs and supplements, such as fish oil or turmeric, can do the same, he says. The truth is that there is not enough scientific evidence to substantiate these claims, and the medical community doesnt know for sure how diet impacts psoriatic disease.
What the medical community does agree on, however, is that people with psoriatic disease should maintain a healthy weight, and thats where diet and exercise can play and important role. Research has found that maintaining a healthy weight lowers the risk of developing co-morbidities or related health conditions like diabetes or cardiovascular disease.
Siegel says that another big myth about psoriasis is that there isnt a treatment available for patients to achieve clear or nearly clear skin.
This is simply not true, he says. There have been tremendous advancements and there are currently a number of safe, effective and affordable options. The first step people living with psoriasis should take is to work with their health care provider to discuss a treatment strategy. By following a goal-oriented, trackable treatment strategy, people living with psoriasis should expect to begin seeing results in three to six months.
Adds Beer: Psoriasis is now one of the most researched skin diseases and each year we get better and better treatments. See your dermatologist to get more information.
2017 NewsmaxHealth. All rights reserved.
Posted: at 11:29 pm
PSORIASIS is a common skin condition that causes skin cells to grow too quickly and build up, leaving thick, red, silvery, or scaly patches (plaques) on the surface of the skin. Psoriasis is not contagious so you cant get it from touching someone who has it. Its an accepted fact, but not proven, that men are more prone to suffering from psoriasis than women.
Skin patches with raised edges that are red with silvery-white scales (called plaques), rashes on genitals, scalp, or in skin folds (such as the folds you have on your knees and elbows), itching, pain, dry, cracked skin that may bleed, thickened, pitted, or discoloured nails, swollen, painful joints (psoriatic arthritis).
For most people, psoriasis patches vary in size. They can range from small spots with dandruff-like flakes to wide patches that cover large areas of skin. Mild psoriasis can be annoying, but severe cases can be disfiguring, painful, and sometimes disabling. Flares (when psoriasis gets worse) occur in cycles, with symptoms that last for weeks to months and may then lessen for some time before coming back.
Medical researchers believe that psoriasis is a chronic autoimmune skin disease; however, it has also been linked to genetic and environmental factors.
There are certain things that can trigger a psoriasis flare-up (when the psoriasis becomes worse). Such as: Certain infections (such as strep throat), certain medicines (for high blood pressure), stress, smoking, cold, dry weather, alcohol and injury to skin (insect bites/cuts/burns, etc.)
There isnt a cure for psoriasis, but there are many good ways to keep the symptoms under control with the most important being general cleanliness of the skin.
Psoriasis symptoms and causes – RTN Newspaper
Posted: at 11:29 pm
Dr. Reddy’s Laboratories announces the out-licensing of DFD-06 to Encore Dermatology.
Dr. Reddys Laboratories Ltd., through its wholly owned subsidiary Promius Pharma, LLC, announced today that it has out-licensed the future development, manufacturing, and commercialization rights of DFD-06, a topical high potency steroid, to Encore Dermatology Inc. The drug is intended to be used for treatment of moderate to severe plaque psoriasis.
Under the terms of the agreement, Encore will be responsible for the commercialization of DFD-06 in the United States. Promius Pharma is eligible to receive certain pre- and post- commercialization milestone payments of up to $32.5 million, followed by fixed royalty payments on net sales.
We believe Encore and its management team are well positioned to realize the full potential of this asset DFD-06. We look forward to obtaining NDA approval this fall, enabling Encores management team to quickly deliver this product to the providers and their patients, says Anil Namboodiripad, Ph.D., senior vice president, proprietary products, and president, Promius Pharma.
(Source: Business Wire)
Arteric Develops Website Centerpiece of Award-Winning Psoriasis Patient Activation Campaign – Benzinga
Posted: at 11:29 pm
Summit, NJ, August 21, 2017 –(PR.com)– Arteric (http://arteric.com), a digital healthcare marketing agency that fuses exceptional software development skill with healthcare marketing expertise to help brands connect patients, caregivers, and healthcare professionals with the health information and tools that patients need to live longer, healthier lives proudly announces that the patient activation campaign Rise Up Against Psoriasis won a coveted Golden Scalpel award. In collaboration with McCann Health London and McCann Wien, Arteric developed and implemented the campaign’s website centerpiece (riseagainstpsoriasis.com/de) for Celgene sterreich (Celgene Austria). The strategic process behind this award-winning collaboration is described in detail at arteric.com.
Presented by Pharma Marketing Club Austria, the Golden Scalpel awards represent best-in-class pharmaceutical advertising in Austria. Two juries of industry experts – one with general marketing expertise and the other with digital marketing expertise – selected award recipients. Rise Up Against Psoriasis received a Golden Scalpel in the category Digital Media non-RX/non-OTC.
Psoriasis poses risks that go far beyond skin lesions. Research findings point to an increased risk of depression, anxiety, and risk of suicide in people with psoriasis.  The Rise Up Against Psoriasis campaign was developed to activate patients who had disengaged from the healthcare system.
The website accomplishes this through 4 tactics:
1. A short movie follows 3 people through their daily struggles to help psoriasis sufferers recognize that they are not alone. 2. A quiz helps psoriasis sufferers quantify the impact of the disease on their daily lives. 3. A physician finder connects psoriasis sufferers to local dermatologists. 4. A discussion guide creates the foundation for a successful conversation with the physician.
These tactics are delivered through a beautifully designed responsive website that is instrumented to track engagement and provide insights about visitors, to guide future campaign development.
Arteric’s president, Hans Kaspersetz, explains, “Rise Up Against Psoriasis has been successful because it authentically speaks to the psoriasis sufferer’s daily struggles with the disease – it calls out to all those directly and indirectly affected by psoriasis, sending the essential message that help is available. The website invites site visitors to complete the Dermatology Life Quality Index survey to assess the impact of psoriasis on their quality of life, helping to build context for a conversation with their doctor.”
Mr. Kaspersetz continues, “Arteric has a robust global digital marketing practice with clients in North America, the EU, Asia, and Australia. For more than a decade, we’ve created websites and digital campaigns for audiences all over the world. Our team has delivered digital assets in 28 languages in 35 markets. We’re especially pleased to create locally recognized best-in-class work with international partners like McCann Health London.”
Jonathan Kukathasan, General Manager of McCann Health London, concurs. “While developing the Rise Up Against Psoriasis campaign, we worked alongside key partners to ensure it was a success. As the creative agency, we enjoyed working with Arteric, which played a critical role. It was great working alongside them to create this campaign and we look forward to working with them in the future.”
Mr. Kaspersetz summarizes the effort this way. “The award validates the years of effort we’ve invested in understanding global needs and local markets. Whether in the US or in Austria, our goal is to connect people with the health information and resources they need to live longer, healthier lives.”
For two decades, Arteric has worked directly with healthcare clients and partnered seamlessly with their service providers to develop award-winning websites, mobile apps, and Web applications that work everywhere and every time to help brands win. Contact Hans Kaspersetz at 201.558.9910 to put Arteric’s digital marketing expertise to work for your brand.
Learn more about Rise Up Against Psoriasis at http://www.riseagainstpsoriasis.com/de.
About Arteric Arteric is a digital healthcare marketing agency built on a foundation of technology expertise – digital strategy, software engineering, search engine optimization, and search engine marketing. Arteric develops the strategy and the software -websites, mobile apps, and Web applications – that drive pharmaceutical and biotechnology digital marketing campaigns and connect the public and healthcare professionals with information about life-changing therapies, technologies, and devices.
References 1. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891-895. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928071/. Accessed August 18, 2017. 2. Findlay A, Khan G. Dermatology Life Quality Index (DLQI). 1992. Available at http://www.bad.org.uk/shared/get-file.ashx?id=1653&itemtype=document. Accessed August 21, 2017.
Contact Information: Arteric Ross O’Shea 201.546.9910 Contact via Email http://arteric.com
Read the full story here: http://www.pr.com/press-release/727344
Press Release Distributed by PR.com